New Haven, Conn. based Achillion Pharmaceuticals, a biopharmaceutical company currently focused on developing treatment for hepatitis C, has appointed David Apelian, MD, as its chief medical officer.
Dr. Apelian has previously served as clinical director of infectious disease at Bristol-Myers Squibb, New York-based biopharmaceutical company, and clinical director of hepatology and gastroenterology at Schering Plough, New Jersey-based pharmaceutical company that has since merged with Merck & Co.
He will head the clinical development of Achillion's hepatitis C treatments.
More Articles on Gastroenterology:
Vision-Sciences Names Howard Zauberman Interim CEO
Dr. Allen Kamrava to Invest, Practice at La Peer Health Systems
Dr. Roger Klein Joins Summit Medical Group
Dr. Apelian has previously served as clinical director of infectious disease at Bristol-Myers Squibb, New York-based biopharmaceutical company, and clinical director of hepatology and gastroenterology at Schering Plough, New Jersey-based pharmaceutical company that has since merged with Merck & Co.
He will head the clinical development of Achillion's hepatitis C treatments.
More Articles on Gastroenterology:
Vision-Sciences Names Howard Zauberman Interim CEO
Dr. Allen Kamrava to Invest, Practice at La Peer Health Systems
Dr. Roger Klein Joins Summit Medical Group